Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > News > Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery
  • News

Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery

  • 14 October 2021
  • Janet Fricker
Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery
Total
0
Shares
0
0
0
0
0

Patients with non-immunogenic cancers, such as breast and gynaecological cancers, who are given the anti-nausea drug dexamethasone during surgery survive longer. The study, abstract 4224, presented at the Anesthesiology 2021 annual meeting, held October 8 to 12, San Diego, found that the risk of dying within 90 days after cancer surgery was 32% lower in patients who received dexamethasone compared to those not receiving the drug.

“Based on our data, physician anaesthesiologists should feel more confident in administering dexamethasone to patients undergoing surgery for cancers that have little interaction with the immune system,” said study senior author Maximilian Schaefer, from Beth Israel Deaconess Medical Center and Harvard Medical School, Boston. “It does not only prevent nausea, but may also improve survival.”

At the beginning of surgery dexamethasone is administered as a prophylactic medication (single bolus intravenously) to prevent postoperative nausea and/ or vomiting. Whether or not dexamethasone is used is at the discretion of anaesthesiologists.

Dexamethasone, a glucocorticoid available since 1958, is known to dampen the immune system. Studies have also suggested that dexamethasone can prevent cancer growth via direct effects on the tumour. However, previous clinical studies have produced conflicting results, with some reporting higher survival and others lower survival after dexamethasone use.

The explanation for these differing effects, Schaefer hypothesized, is that in cancers where the immune system suppresses growth, inhibiting the immune system with dexamethasone would have a negative effect on tumour control, cancelling out the positive effect. However, in non-immunogenic cancers, direct effect on the cancer would go unhindered.

For the current study, Schaefer and his team analysed the records of 74,058 patients who underwent surgery to remove non-immunogenic cancers at Beth Israel Deaconess Medical Center (between 2005 and 2020) and Massachusetts General Hospital Boston (between 2007 and 2015).

Overall, 25,178 (34%) received dexamethasone during surgery. After 90 days, 209 (0.83%) of patients who had received dexamethasone died compared with 1,543 (3.2%) who had not received the drug. When statistical modelling took into account confounders (such as patient demographics, comorbidities, intraoperative factors, preoperative steroid use and chemotherapy) preoperative dexamethasone administration was associated with decreased risk of 90-day mortality with an adjusted odds ratio (aOR) of 0.68 (95% CI 0.57-0.81; p<0.001).

Subgroup analyses showed that dexamethasone was particularly beneficial for patients with breast cancer (aOR=0.22; 95% CI 0.11-0.45; p<0.001), and gynaecological malignancies (ovary, uterus, cervix), (aOR=0.33; 95% CI 0.16-0.66; p=0.002).

“Ours is the first large study to show that for a wide variety of cancers where the immune system does not play a major role, the positive effects seem to predominate,” said Schaefer. The next step, he added, will be to verify the results for dexamethasone in larger national datasets and also explore the effects of different anti-inflammatory drugs administered during surgery for cancer.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • anti-inflammatory drugs
  • cancer surgery
  • cancer survivors
  • dexamethasone
  • non-immunogenic cancers
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Voices

When your patient tells you they’re still not better, please accept what they say

  • 14 October 2021
  • Cordelia Galgut
View Post
Next Article
  • News

What’s new in lung and colorectal cancer? reports from ESMO 2021

  • 15 October 2021
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma

  • Janet Fricker
  • 4 July 2025
View Post
  • News

CancerWorld #105 (July 2025)

  • Yeva Margaryan
  • 2 July 2025
View Post
  • News

How a Chicken Egg Model Could Transform Pediatric Cancer Treatment in Canada

  • Victoria Forster
  • 20 June 2025
View Post
  • News

Microbiota-Derived Bile Acids as Androgen Receptor Antagonists Enhance Anti-Tumour Immunity

  • Janet Fricker
  • 19 June 2025
View Post
  • Articles
  • News

Strategies Needed to Prioritise Screening in Survivors of Childhood Cancer

  • Janet Fricker
  • 4 June 2025
View Post
  • Articles
  • News

CancerWorld #104 (June 2025)

  • Yeva Margaryan
  • 2 June 2025
View Post
  • Articles
  • Medicine
  • News

Common Diabetes Medication Could Protect Heart Health During Cancer Treatment

  • Janet Fricker
  • 30 May 2025
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
search
CancerWorld #105 Download CancerWorld #104 Download CancerWorld #103 Download CancerWorld #102 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma
    • 4 July 2025
  • CancerWorld #105 (July 2025)
    • 2 July 2025
  • How a Chicken Egg Model Could Transform Pediatric Cancer Treatment in Canada
    • 20 June 2025
  • Microbiota-Derived Bile Acids as Androgen Receptor Antagonists Enhance Anti-Tumour Immunity
    • 19 June 2025
  • Strategies Needed to Prioritise Screening in Survivors of Childhood Cancer
    • 4 June 2025
Article
  • Suheir Rasul: Protecting Human Dignity
    • 4 July 2025
  • Equity:The Word That Shaped Her Career From The Lab To The White House:The Story Of Catharine Young
    • 4 July 2025
  • Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
    • 3 July 2025
Social

Would you follow us ?

Contents
  • Suheir Rasul: Protecting Human Dignity
    • 4 July 2025
  • Equity:The Word That Shaped Her Career From The Lab To The White House:The Story Of Catharine Young
    • 4 July 2025
  • Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
    • 3 July 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.